AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer.

Cancers (Basel) · 2019 · PMC6628138 · PMID 31181609

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

a positive trendp = 0.090so close (0.05 < p ≤ 0.1)

BRAF mutation status significantly associated with RAI-R tumors ( p = 0.010, Table 2 ) and showed only a positive trend of statistical association with disease recurrence/persistence ( p = 0.090), as previously shown [ 1 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.